JP2018070625A5 - - Google Patents

Download PDF

Info

Publication number
JP2018070625A5
JP2018070625A5 JP2017224413A JP2017224413A JP2018070625A5 JP 2018070625 A5 JP2018070625 A5 JP 2018070625A5 JP 2017224413 A JP2017224413 A JP 2017224413A JP 2017224413 A JP2017224413 A JP 2017224413A JP 2018070625 A5 JP2018070625 A5 JP 2018070625A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
amino acids
seq
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017224413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018070625A (ja
JP6803315B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018070625A publication Critical patent/JP2018070625A/ja
Publication of JP2018070625A5 publication Critical patent/JP2018070625A5/ja
Application granted granted Critical
Publication of JP6803315B2 publication Critical patent/JP6803315B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017224413A 2011-04-20 2017-11-22 エンドグリンポリペプチドおよびその使用 Expired - Fee Related JP6803315B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477585P 2011-04-20 2011-04-20
US61/477,585 2011-04-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014506553A Division JP6250533B2 (ja) 2011-04-20 2012-04-19 エンドグリンポリペプチドおよびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020134862A Division JP7097930B2 (ja) 2011-04-20 2020-08-07 エンドグリンポリペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2018070625A JP2018070625A (ja) 2018-05-10
JP2018070625A5 true JP2018070625A5 (enExample) 2018-10-11
JP6803315B2 JP6803315B2 (ja) 2020-12-23

Family

ID=46000405

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014506553A Expired - Fee Related JP6250533B2 (ja) 2011-04-20 2012-04-19 エンドグリンポリペプチドおよびその使用
JP2017224413A Expired - Fee Related JP6803315B2 (ja) 2011-04-20 2017-11-22 エンドグリンポリペプチドおよびその使用
JP2020134862A Expired - Fee Related JP7097930B2 (ja) 2011-04-20 2020-08-07 エンドグリンポリペプチドおよびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014506553A Expired - Fee Related JP6250533B2 (ja) 2011-04-20 2012-04-19 エンドグリンポリペプチドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020134862A Expired - Fee Related JP7097930B2 (ja) 2011-04-20 2020-08-07 エンドグリンポリペプチドおよびその使用

Country Status (8)

Country Link
US (3) US9932386B2 (enExample)
EP (2) EP3549952A1 (enExample)
JP (3) JP6250533B2 (enExample)
CN (3) CN108178789B (enExample)
AU (4) AU2012245439B2 (enExample)
CA (1) CA2833747C (enExample)
DK (1) DK2699590T3 (enExample)
WO (1) WO2012145539A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP3549952A1 (en) 2011-04-20 2019-10-09 Acceleron Pharma Inc. Endoglin polypeptides and uses thereof
WO2013019805A1 (en) 2011-08-01 2013-02-07 Tufts Medical Center, Inc. Treatment of heart failure and related conditions
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
WO2015042269A1 (en) * 2013-09-20 2015-03-26 Tufts Medical Center, Inc. Methods and compositions for reducing cardiac damage and other conditions
AU2014339898B2 (en) * 2013-10-25 2020-07-23 Acceleron Pharma, Inc. Endoglin peptides to treat fibrotic diseases
CN120919282A (zh) 2013-11-21 2025-11-11 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
CN113403338B (zh) * 2014-03-28 2025-07-15 华盛顿大学商业中心 乳腺癌和卵巢癌疫苗
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
CN106794233B (zh) 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
CN110317264B (zh) * 2015-11-10 2022-10-11 孙嘉琳 一种抗肿瘤蛋白内皮抑素的衍生物
WO2017176938A1 (en) * 2016-04-06 2017-10-12 Acceleron Pharma, Inc. Bmprii polypeptides and uses thereof
AU2017293778B2 (en) * 2016-07-07 2022-03-24 Acceleron Pharma Inc. TGF-beta superfamily heteromultimers and uses thereof
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
WO2019136043A1 (en) * 2018-01-03 2019-07-11 Acceleron Pharma Inc. Single-arm co-receptor fusion proteins and uses thereof
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
US20220195500A1 (en) * 2019-04-26 2022-06-23 Vanderbilt University Probes for detecting rna and methods of use thereof
EP4009953A4 (en) * 2019-08-07 2023-08-23 Icahn School of Medicine at Mount Sinai METHOD OF TREATMENT OF KELOIDS
EP4081240A4 (en) * 2019-12-03 2023-12-06 Acceleron Pharma Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONARY HYPERTENSION
WO2021167952A2 (en) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
KR20220021207A (ko) 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
US20220233714A1 (en) * 2021-01-27 2022-07-28 Vanderbilt University Nanogold-dna bioconjugates and methods of use thereof
CN116482374B (zh) * 2022-12-12 2026-03-27 北京谱峰源生物科技有限公司 用于肝纤维化早期诊断的蛋白和检测试剂盒

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
JPH08504577A (ja) * 1992-10-30 1996-05-21 エイチエスシー リサーチ アンド ディベロプメント リミテッド パートナーシップ ＴＧＦ−βの制御活性を改変するための組成物および方法
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6423501B2 (en) 1996-12-13 2002-07-23 Beth Israel Deaconess Medical Center Calcium-independent negative regulation by CD81 of receptor signaling
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
CN104231078A (zh) 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
PT1292335E (pt) 2000-06-23 2007-08-13 Bayer Schering Pharma Ag Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii)
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
KR100976076B1 (ko) 2003-05-22 2010-08-17 아보트 러보러터리즈 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
WO2007143023A1 (en) * 2006-05-31 2007-12-13 Beth Israel Deaconess Medical Center Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer
KR20170012582A (ko) 2006-11-02 2017-02-02 악셀레론 파마 인코포레이티드 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
EP2150560A1 (en) * 2007-06-01 2010-02-10 Wyeth Methods and compositions for modulating bmp-10 activity
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
US20100210713A1 (en) 2009-01-16 2010-08-19 The General Hospital Corporation Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor
CN102548617B (zh) * 2009-03-30 2017-11-07 阿塞勒隆制药公司 Bmp‑alk3拮抗剂和促进骨生长的用途
WO2010128158A1 (en) * 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders
US8795663B2 (en) * 2010-01-12 2014-08-05 Beth Israel Deaconess Medical Center, Inc. Soluble endoglin and uses thereof
EP3549952A1 (en) 2011-04-20 2019-10-09 Acceleron Pharma Inc. Endoglin polypeptides and uses thereof
WO2013019805A1 (en) 2011-08-01 2013-02-07 Tufts Medical Center, Inc. Treatment of heart failure and related conditions
WO2015042269A1 (en) 2013-09-20 2015-03-26 Tufts Medical Center, Inc. Methods and compositions for reducing cardiac damage and other conditions
AU2014339898B2 (en) 2013-10-25 2020-07-23 Acceleron Pharma, Inc. Endoglin peptides to treat fibrotic diseases
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP7725551B2 (ja) アクチビンｉｉａ型受容体変異体を含む医薬組成物
JP7365715B2 (ja) 組織修復のための二重特異性治療用タンパク質
JP2020506693A5 (enExample)
RU2725812C2 (ru) Конструкции полиспецифических антител
JP5996631B2 (ja) ＴＮＦＲ：Ｆｃ融合タンパク質の安定した医薬液剤
US20110250215A1 (en) Structurally-related relaxin-fusion proteins with extended in vivo half-lives
US20230348565A1 (en) Methods of using activin receptor type ii variants
AU2018201273A1 (en) Fibronectin based scaffold domain proteins that bind to myostatin
CN106661128A (zh) 构建氨基末端免疫球蛋白融合蛋白的方法及其组合物
JP6431844B2 (ja) Ｔｎｆｒ：ｆｃ融合プロテインの安定な医薬組成物
CN106687478A (zh) 新的抗人Tie‑2抗体
JP2018537093A5 (enExample)
EP3013366A1 (en) Combination therapy using a factor xii inhibitor and a c1-inhibitor
JP2008521426A5 (enExample)
WO2017059371A1 (en) Treatment of bile acid disorders
Freches et al. PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab’antibody fragment after pulmonary delivery in three different species
JP2024546877A (ja) ヘテロ二量体リラキシン融合物を使用した治療
JP7804590B2 (ja) 抗ｉｌ－３３抗体の処方物
JP7839117B2 (ja) 抗プロテインｓシングルドメイン抗体及びそれを含むポリペプチド
US20250304675A1 (en) Compositions and methods for treating ischemic heart disease
AU2022276188A1 (en) Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
RU2022122493A (ru) Антитело против адреномедуллина (adm), или фрагмент антитела против adm, или анти-adm не-ig каркас для применения в терапии или профилактике шока
JP2026507086A5 (enExample)
JP2025539794A (ja) 二重機能タンパク質およびその使用
HK40049107B (en) Activin receptor type iia variants and methods of use thereof